Novel platelet ADP P2Y12 inhibitors in the treatment of acute coronary syndrome. - Wikidata - awgldk - TriplyDB

Novel platelet ADP P2Y12 inhibitors in the treatment of acute coronary syndrome.

Novel platelet ADP P2Y12 inhibitors in the treatment of acute coronary syndrome.

http://www.wikidata.org/entity/Q37925007

about

Potent and Orally Bioavailable Antiplatelet Agent, PLD-301, with the Potential of Overcoming Clopidogrel Resistance Role of Pannexin-1 hemichannels and purinergic receptors in the pathogenesis of human diseases.

P2860

Q37204050-55FC281A-A6C3-4E1E-A05A-5F6FD3026ECB Q37636397-ED224199-7F21-4342-A8C1-8A67C0D5346E

P2860

Novel platelet ADP P2Y12 inhibitors in the treatment of acute coronary syndrome.

http://www.wikidata.org/entity/Q37925007

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Novel platelet ADP P2Y12 inhibitors in the treatment of acute coronary syndrome.

@en

Novel platelet ADP P2Y12 inhibitors in the treatment of acute coronary syndrome.

@nl

type

label

Novel platelet ADP P2Y12 inhibitors in the treatment of acute coronary syndrome.

@en

Novel platelet ADP P2Y12 inhibitors in the treatment of acute coronary syndrome.

@nl

prefLabel

Novel platelet ADP P2Y12 inhibitors in the treatment of acute coronary syndrome.

@en

Novel platelet ADP P2Y12 inhibitors in the treatment of acute coronary syndrome.

@nl

P1433

Q37925007-8837BF00-109F-4EF4-8FDC-E7F70ED64168

P1476

Q37925007-C35229DA-8452-4747-8A1F-F691D2452977

P2093

Q37925007-1C48E585-5C4A-4FD7-B873-165924D7F535

Q37925007-C8EA04AC-5E0F-488D-8C0C-5EC2ADCD3ED3

Q37925007-E26C4A8A-6F5D-4967-A667-535B382A5664

P2860

Q37925007-06C760CC-5D3D-44A1-A1D8-FE89CED4C50F

Q37925007-0FC6BAE0-23FC-41F1-BEB6-DF68FA8B223A

Q37925007-117F909A-C532-4B3F-ACDC-68A1EC0CFA78

Q37925007-15F2AB2E-9FD8-4AEC-AF2B-35F3FE90E566

Q37925007-21E810FA-9BF0-463E-82DA-F1013E298FE8

Q37925007-269D5449-149F-4BFB-9F11-A7A9089CE2A5

Q37925007-3479A6E7-6FCC-4961-98F0-A9EB261E9B7F

Q37925007-3831A309-A755-43AD-B9C3-7D0AD1443926

Q37925007-3CC3FC5B-ACC3-4870-AFAA-A9D363B09BED

Q37925007-4B660031-6AB8-420F-A8DA-F51D1B7B109D

P304

Q37925007-0153B2AC-3457-49A0-9805-34BEB8D48E3E

P31

Q37925007-CD9700AF-164B-4A12-A295-4755D816D64D

P356

Q37925007-72984E9D-F4C0-4F7A-B28D-78CD967DAFBF

P433

Q37925007-9B376FD7-AE7A-4BEC-BFD4-2B18ED50CCC3

P478

Q37925007-618D998C-0C16-4D67-B699-AAEAE910D141

P577

Q37925007-DEF9EFE4-EACF-49A0-A889-31BDE7FB52F5

P5875

Q37925007-48FF8ABF-8A8E-4B54-9058-8527A5BBA572

P698

Q37925007-5440FE38-8657-4050-9A5F-0EA52A63B285

P356

J.1755-5922.2011.00262.X

P1433

Cardiovascular Therapeutics

P1476

Novel platelet ADP P2Y12 inhibitors in the treatment of acute coronary syndrome.

@en

P2093

Bryan P Yan

http://www.w3.org/2001/XMLSchema#string

Guang-Ming Tan

http://www.w3.org/2001/XMLSchema#string

Yat-Yin Lam

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity

Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin

Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial

Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

Usefulness of clopidogrel in abolishing the increased risk of reinfarction associated with higher platelet counts in patients with ST-elevation myocardial infarction (results from CLARITY-TIMI 28)

Antiplatelet therapy preceding coronary artery surgery: implications for bleeding, transfusion requirements and outcome

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

P304

e167-73

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1755-5922.2011.00262.X

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P577

2011-07-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51612327

http://www.w3.org/2001/XMLSchema#string

P698

21883998

http://www.w3.org/2001/XMLSchema#string